Wynik wyszukiwania w bazie Polska Bibliografia Lekarska GBL

Zapytanie: KRZYSTYNIAK
Liczba odnalezionych rekordów: 1



Przejście do opcji zmiany formatu | Wyświetlenie wyników w wersji do druku
1/1

Tytuł oryginału: Current stratetgies for anticancer chemoprevention and chemoprotection.
Autorzy: Krzystyniak Krzysztof L.
Źródło: Acta Pol. Pharm. 2002: 59 (6) s.473-478, tab., bibliogr. 32 poz. - 3 Multidyscyplinarna Konferencja nt. badań nad lekami Piła 13-16.05. 2002
Sygnatura GBL: 301,378

Hasła klasyfikacyjne GBL:
  • farmacja
  • onkologia

    Typ dokumentu:
  • praca związana ze zjazdem
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • ludzie
  • zwierzęta

    Streszczenie angielskie: Relatively new targets in drug design projects in cancer pharmacology include cytostatic agents, immune system modulators, and angiogenesis inhibitors. Preventive oncology applies pharmacological agents to reverse, retard, or halt progression of neoplastic cells to invasive malignancy. Prevention of cancer, however, can be accomplished through many strategies, including changes in diet and lifestyle. For example, The vast majority of lung cancers (80-90 p.c.) can be attributed to cigarette smoking and therefore, the most effective primary preventive strategy for lung cancer is to quit smoking. Chemoprevention through interruption of multistage carcinogenesis include different molecular targets. Selective estrogen receptor modulators (SERMs) act as estrogen receptor (ER) agonists. Ligands for the peroxisome proliferator-activated receptor gamma (PPAR-gamma) suppress breast carcinogenesis in experimental models and induce differentiation of human liposarcoma cells. Selective PPAR modulators (SPARMs), by analogy to the SERM concept, are designed to have desired effects on specific genes relevant to carcinogenesis. Enzymatic approach in endocrine-related tumors involve inhibition of aromatase to prevent breast cancer and inhibition of 5-alpha-reductase to prvent prostate cancer. Down-regulation of inflammatory prostaglands synthesis by inhibition of cyclooxygenase -2 (COX-2), inhibition of the inducible nitric oxide synthase (iNOS), and simulation of phase II detoxication system, are currently examined in experimental models and clinical trials...

    stosując format: